Triple-negative breast cancer and the need for new therapeutic targets

Area of Science:

• Oncology
• Genomics
• Molecular Biology

Background:

• Triple-negative breast cancers (TNBCs) represent a heterogeneous and aggressive subtype of breast cancer, defined by the absence of estrogen receptors, progesterone receptors, and HER2 amplification.
• While some TNBCs respond to chemotherapy, many exhibit poor prognoses, highlighting the need for more effective treatment strategies.
• Decades of research have uncovered significant molecular heterogeneity within TNBCs, necessitating advanced classification methods.

Purpose of the Study:

• To review current knowledge on the clinical characteristics and molecular alterations of TNBCs.
• To discuss conventional therapeutic strategies and emerging targeted therapy approaches for TNBCs.
• To integrate recent findings on molecular characterization to inform future treatment selection.

Main Methods:

• Review of existing literature on TNBC clinical characteristics and molecular alterations.
• Analysis of high-throughput molecular data, including genomic and transcriptomic analyses.
• Synthesis of information on conventional and targeted therapeutic strategies.

Main Results:

• TNBCs are molecularly diverse, with distinct subgroups identified through advanced analyses.
• Understanding these molecular alterations is key to predicting treatment response and prognosis.
• Current research focuses on leveraging this molecular knowledge for personalized therapy selection.

Conclusions:

• TNBCs require tailored treatment strategies based on their specific molecular profiles.
• Continued research into molecular characterization is essential for advancing TNBC therapy.
• Integrating genomic and transcriptomic data holds promise for improving outcomes in TNBC patients.